Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCB 002

Next Previous
Drug Profile

TCB 002

Alternative Names: Ex-vivo expanded allogeneic γδ T-lymphocytes - TC Biopharm; OmnImmune; TCB-002

Latest Information Update: 06 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TC BioPharm
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Acute myeloid leukaemia

Most Recent Events

  • 25 Oct 2023 TC BioPharm plans a ACHIEVE2 clinical trial beyond acute myeloid leukemia in USA in 2024
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in Czech Republic (Parenteral, Infusion)
  • 23 Mar 2022 TC BioPharm receives MHRA and Research Ethics Committee approvals to initiate a phase IIb/III trial for Acute myeloid leukaemia in United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top